Your browser doesn't support javascript.
loading
Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study.
Qin, Qin; Ge, Xiaolin; Wang, Xin; Wang, Lan; Li, Chen; Chen, Junqiang; Wang, Xiaomin; Zhao, Yidian; Zhang, Wencheng; Wang, Ping; Pang, Qingsong; Zhang, Kaixian; Li, Ling; Hu, Miaomiao; Hao, Chongli; Li, Gaofeng; Xu, Yonggang; Qiao, Xueying; Zhou, Zhiguo; Zhu, Shuchai; Shen, Wenbin; Wang, Yati; Lu, Na; Liu, Miaoling; Qie, Shuai; Han, Chun; Xiao, Zefen; Sun, Xinchen.
Afiliación
  • Qin Q; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Ge X; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Wang X; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang L; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Li C; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen J; Department of Radiation Oncology, Fujian Cancer Hospital/Fujian Medical University Cancer Hospital, Fuzhou, China.
  • Wang X; Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
  • Zhao Y; Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
  • Zhang W; Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, China.
  • Wang P; Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, China.
  • Pang Q; Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, China.
  • Zhang K; Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
  • Li L; Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
  • Hu M; Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
  • Hao C; Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
  • Li G; Department of Radiation Oncology, National Center of Gerontology, Beijing Hospital, Beijing, China.
  • Xu Y; Department of Radiation Oncology, National Center of Gerontology, Beijing Hospital, Beijing, China.
  • Qiao X; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Zhou Z; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Zhu S; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Shen W; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Wang Y; Department of Radiation Oncology, The Seventh Medical Center of People's Liberation Army of China General Hospital, Beijing, China.
  • Lu N; Department of Radiation Oncology, The Seventh Medical Center of People's Liberation Army of China General Hospital, Beijing, China.
  • Liu M; Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
  • Qie S; Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
  • Han C; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Xiao Z; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Sun X; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Oncol ; 10: 580450, 2020.
Article en En | MEDLINE | ID: mdl-33123483
ABSTRACT

Aim:

To evaluate long-term outcome and prognostic factors of stage III esophageal cancer after definitive radiotherapy using three dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) techniques.

Methods:

Patients with T3N1M0/T4N0-1M0 esophageal squamous cell carcinoma (ESCC) treated with definitive radiotherapy from 2002 to 2016 in 10 Chinese medical centers were retrospectively analyzed. Overall survival (OS) and progression-free survival (PFS) rates were calculated. Prognostic factors were analyzed by Log-rank test and multivariable Cox model.

Results:

Survival data of 1,450 patients were retrospectively collected. With a median follow-up time of 65.9 months, 1-, 3-, and 5-year OS rates were 69.3, 36.7, and 27.7%, respectively, and PFS rates were 58.6, 32.7, and 27.4%, respectively. Univariable analyses showed that gender, age, lesion location, lesion length, largest tumor diameter, lymph node metastasis, gross tumor volume, EQD2, short-term response, and concurrent chemotherapy were prognostic factors for OS. Multivariable analyses showed that lesion location, T-classification, GTV size, EQD2, and short-term response to RT were independent prognostic factors for OS, and tumor diameter, GTV size, and short-term response were independent prognostic factors for PFS.

Conclusions:

This study demonstrated that definitive radiotherapy using 3DCRT and IMRT provides promising outcomes for locally advanced ESCC.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: China